Health

STAT+: FDA rejects Capricor Therapeutics’ Duchenne therapy, a decision that was a long time coming

The Food and Drug Administration said Friday that it had rejected a cell therapy intended for patients with Duchenne muscular dystrophy developed by Capricor Therapeutics.

✦ Extractive summary — built from the sources' own reporting•From 1 source•1 min read•Updated November 20, 2026, 11:43 PM UTC
Key points
  • But nothing is straightforward when it comes to regulating drugs for Duchenne, a progressive, muscle-wasting disease.
  • Continue to STAT+ to read the full story….
  • Both failed to show deramiocel could stave off heart failure or preserve muscle function in their arms.

The targeted patient population — teenagers and young men with Duchenne who had already lost the ability to walk — have few treatment options today.

The decision to block the treatment, called deramiocel, from reaching the market should have been an easy one for regulators to make.

How this summary was made: extractive summary — built from the sources' own reporting. It is drawn only from the reporting of the sources listed below — read the originals for full detail. How we summarize →

Advertisement

Every article behind this summary — 1 article from 1 outlet